The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines-Reference-Cited by-同舟云学术

The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines

Published:2010-06-09 Issue:6 Volume:29 Page:1224-1229
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Budman Daniel R.,Tai Julia,Calabro Anthony,John Veena

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-010-9467-6.pdf

Reference38 articles.

1. UCSW G (2009) United States Cancer Statistics: 1999–2005 incidence and mortality. Web Based Report, 2009

2. Winter-Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev CD004706

3. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y (2008) Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. J Natl Cancer Inst 100:399–406

4. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428

5. Collinson F, Jayson G (2009) New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol 21:44–53

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines;PLOS ONE;2022-07-08

2. Quadruple-responsive nanoparticle-mediated targeted combination chemotherapy for metastatic breast cancer;Nanoscale;2021

3. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents;Current Medicinal Chemistry;2020-06-02

4. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy;Cancers;2019-09-07

5. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer;Gynecologic Oncology Reports;2019-08